Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Inogen ( (INGN) ) is now available.
Inogen reported its fourth-quarter and full-year 2025 results on February 24, 2026, showing 2025 revenue up 3.9% to $348.7 million, driven by strong international portable oxygen concentrator sales, and a sharply reduced GAAP net loss of $22.7 million with positive adjusted EBITDA of $2.7 million. The company introduced new products including the Voxi 5 concentrator, Aurora CPAP masks, and the Simeox airway clearance device, expanded digital tools and a China-focused collaboration with Yuwell Medical, and its board approved on February 20, 2026 a share repurchase program of up to $30 million, underscoring improved balance sheet strength and positioning Inogen to pursue mid-single-digit revenue growth and further profitability gains in 2026.
Inogen’s fourth-quarter 2025 revenue grew 2.0% to $81.7 million, with margin pressure from channel mix but improved operating loss, reflecting material cost reductions and operational efficiencies. Year-end cash and marketable securities of $120.9 million with no debt, combined with refined reporting of U.S. sales, international sales, and U.S. rentals, highlight a business shifting toward higher-growth international channels while seeking to return capital to shareholders and enhance long-term value creation.
The most recent analyst rating on (INGN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Inogen stock, see the INGN Stock Forecast page.
Spark’s Take on INGN Stock
According to Spark, TipRanks’ AI Analyst, INGN is a Neutral.
The score is held down primarily by still-negative profitability and TTM cash flow despite improving revenue and margins, while a low-leverage balance sheet provides some support. Technicals are neutral and do not add strong confirmation. The earnings call was a relative positive with continued revenue growth and adjusted EBITDA profitability, but valuation remains challenged due to losses and no dividend.
To see Spark’s full report on INGN stock, click here.
More about Inogen
Inogen, Inc. is a global medical technology company focused on innovative respiratory products for use in the homecare setting. It develops, manufactures, and markets respiratory therapy devices for patients with chronic respiratory conditions, working with patients, prescribers, home medical equipment providers, and distributors to broaden access to its solutions.
Average Trading Volume: 196,168
Technical Sentiment Signal: Sell
Current Market Cap: $158.3M
Find detailed analytics on INGN stock on TipRanks’ Stock Analysis page.